VIA
ALNY icon

Virtus Investment Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Virtus Investment Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.47M Buy
7,471
+5,754
+335% +$1.96M 0.68% 8
2025
Q4 		$683K Buy
1,717
+258
+18% +$114K 0.19% 182
2025
Q3 		$665K Hold
1,459
– – 0.19% 176
2025
Q2 		$476K Sell
1,459
-8
-0.5% -$2.21K 0.16% 187
2025
Q1 		$396K Buy
+1,467
New +$377K 0.11% 209

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus Investment Advisers's ALNY Position: Q1 2026 in Review

Virtus Investment Advisers increased its Alnylam Pharmaceuticals (ALNY) stake by 335% in Q1 2026, buying an estimated $1.96M and bringing the position to 7,471 shares worth $2.47M. The position accounts for 0.68% of the portfolio, ranked #8.

Virtus Investment Advisers first reported a position in ALNY in Q1 2025 and has held it in 5 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Virtus Investment Advisers held 7,471 shares of Alnylam Pharmaceuticals worth $2.47M as of Q1 2026.
  • Virtus Investment Advisers bought 5,754 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.96M.
  • Alnylam Pharmaceuticals made up 0.68% of Virtus Investment Advisers's portfolio in Q1 2026, its #8 holding.
  • Virtus Investment Advisers first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.